An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
September 12th 2013Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
Read More
Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer
June 2nd 2013Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
Evidence for Combining Anti-HER2 Therapies
March 14th 2013Approximately 20% of human breast cancers are characterized by overexpression of the HER2 receptor tyrosine kinase molecule. Multiple anitbodies have been designed to specifically target HER2, and each is able to target the molecule at a different epitope.
Read More
The Future of Antiangiogenic Drugs Hinges on Identification of Biomarkers
March 12th 2013So far, there are no conclusive biomarkers to help identify subsets of patients who would benefit from antiangiogenic therapies, creating a barrier to the use of such treatments, Rugo said in her MBCC abstract.
Read More
The Evolution of Gene Expression Profiling: Its Role in Informing Selection of Systemic Therapy
March 9th 2013Gene expression profiling via the Oncotype DX 21-gene recurrence score assay has been used to assess risk and predict recurrence in hundreds of thousands of women over the course of nearly a decade.
Read More
Exploring New Genomic Targets in Metastatic Disease
March 8th 2013Fabrice André, MD, PhD, has focused his research on translational oncology and the development of novel targeted agents for the treatment of breast cancer through his research as director of INSERM Unit U981 at the Institut Gustave-Roussy in Villejuif, France.
Read More